Ilyang Pharmaceutical Co.,Ltd (007570.KS) Stock
Ilyang Pharmaceutical Co.,Ltd

Company profile
Ilyang Pharmaceutical reported revenue of 272.42 billion KRW for fiscal year 2025, up 1.3% from fiscal year 2024, and net income of 6.90 billion KRW. That is a net profit margin of 2.5% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 65.07 billion KRW, up 5.0% from a year before. South Korea was its largest region in fiscal year 2024, with 82% of revenue. In Q1 2026 it reported net income of 16.80 billion KRW, against net income of 3.54 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 266.67 billion KRW in fiscal year 2023 to 272.42 billion KRW in fiscal year 2025, 1.1% a year on average. Ilyang Pharmaceutical reports about 660 full-time employees.
What stands out
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Ilyang Pharmaceutical Co.,Ltd
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and beverages. In addition, the company offers pharmaceutical raw materials products, such as aluminum hydroxide gel, dried aluminum hydroxide gel, magnesium hydroxide, magnesium hydroxide gel, aluminum hydroxide-magnesium carbonate co-dried gel, magnesium trisilicate, hydrotalcite, almagate, aluminum phosphate, aluminum phosphate gel, aluminum magnesium metasilicate, aluminum magnesium silicate, aluminum magnesium silicopolydrate, magaldrate, magaldrate wet gel, dihydroxy aluminum sodium carbonate, magnesium carbonate, aluminum magnesium hydroxide, synthetic aluminum silicate, and other products. Ilyang Pharmaceutical Co.,Ltd also exports its products. The company was formerly known as Il-Yang Pharm. Ind. Co. and changed its name to Ilyang Pharmaceutical Co., Ltd. in May 1991. Ilyang Pharmaceutical Co.,Ltd was founded in 1946 and is headquartered in Yongin-si, South Korea.
Largest shareholders
- Yoo-Seok Chung15 %15.00%
- Do-Eon Jeong10.45 %10.45%
- Ilyang Pharmaceutical Co.,Ltd6.08%
- Hee-Seok Jeong0.9678 %0.97%
- Jae-hyung Chung0.3494 %0.35%
Share of the company, as of September 25, 2026
Leadership
- Dong-Yeon Kim — CEO, President & Director, 75
- Yoo-Suk Jung — Senior MD & Director, 49
- Kyu-Young Choi — MD & Director, 67
How much revenue does Ilyang Pharmaceutical make?
Ilyang Pharmaceutical reported 272.42 billion KRW in revenue for fiscal year 2025, up 1.3% from 268.86 billion KRW in fiscal year 2024. In Q1 2026 revenue was 65.07 billion KRW.
Where does Ilyang Pharmaceutical make most of its revenue?
South Korea: 82% of revenue by region in fiscal year 2024, followed by Overseas (18%).
What companies are similar to Ilyang Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Dongwha Pharm.Co.,Ltd (000020.KS), Hana Pharm Co., Ltd. (293480.KS), Jeil Pharmaceutical Co.,Ltd (271980.KS), Samsung Pharm. Co., Ltd. (001360.KS).
How has Ilyang Pharmaceutical's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 242.51 billion KRW; FY2022, 247.77 billion KRW; FY2023, 266.67 billion KRW; FY2024, 268.86 billion KRW; FY2025, 272.42 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Ilyang Pharmaceutical Co.,Ltd (007570.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/007570.KS